ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · IEX Real-Time Price · USD
-2.34 (-3.67%)
May 17, 2024, 4:00 PM EDT - Market closed

ANI Pharmaceuticals Revenue

ANI Pharmaceuticals had revenue of $517.46M in the twelve months ending March 31, 2024, with 44.26% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $137.43M with 28.70% year-over-year growth. In the year 2023, ANI Pharmaceuticals had annual revenue of $486.82M with 53.87% growth.

Revenue (ttm)
Revenue Growth
P/S Ratio
Revenue / Employee
Market Cap
1.29B USD

Revenue Chart


Fiscal Year End Revenue Change Growth
Dec 31, 2023486.82M170.43M53.87%
Dec 31, 2022316.39M100.25M46.38%
Dec 31, 2021216.14M7.66M3.67%
Dec 31, 2020208.48M1.93M0.93%
Dec 31, 2019206.55M4.97M2.47%
Dec 31, 2018201.58M24.73M13.99%
Dec 31, 2017176.84M48.22M37.49%
Dec 31, 2016128.62M52.30M68.53%
Dec 31, 201576.32M20.35M36.36%
Dec 31, 201455.97M25.89M86.06%
Dec 31, 201330.08M27.78M1,207.49%
Dec 31, 20122.30M1.87M428.71%
Dec 31, 2011435.16K-2.04M-82.41%
Dec 31, 20102.47M1.22M96.67%
Dec 31, 20091.26M-2.52M-66.73%
Dec 31, 20083.78M3.29M666.82%
Dec 31, 2007493.05K-13.94M-96.59%
Dec 31, 200614.44M14.18M5,496.12%
Dec 31, 2005258.00K180.00K230.77%
Dec 31, 200478.00K12.51K19.09%
Dec 31, 200365.49K-2.70M-97.64%
Dec 31, 20022.77M1.02M58.53%
Dec 31, 20011.75M1.52M667.35%
Dec 31, 2000227.72K29.04K14.61%
Dec 31, 1999198.68K--
Dec 31, 19980--
Dec 31, 19970--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AdaptHealth 3.25B
Brookdale Senior Living 3.05B
BioCryst Pharmaceuticals 355.40M
MiMedx Group 334.51M
MannKind 224.60M
Mirum Pharmaceuticals 224.00M
Gyre Therapeutics 140.62M
Prothena Corporation 89.25M
Revenue Rankings